EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies

Xinyao Wang, Rutao Lin, Qinmei Sun, Xin Xin, Qin Feng

Pharmacological Research · 2026

DOI: 10.1016/j.phrs.2026.108331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026. Verfasst von Xinyao Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Key Laboratory of …. Hauptthemen laut MEDLINE: Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai University of Traditional Chinese Medicine, National Administration of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) represents a major breakthrough in the pharmacotherapy of obesity. However, their single-target mechanism has limitations. In recent years, combination strategies targeting multiple pathways and multiple targets have become a frontier in weight-loss drug development. This review systematically examines GLP-1RA-based combination weight-loss strategies, focusing on the scientific rationale and research progress in two main directions: single-agent multi-target agonists and multi-drug combination therapies. In single-agent multi-target strategies, glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor (GLP-1R/GIPR) dual agonists, glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonists, glucagon-like peptide-1 receptor/amylin receptor (GLP-1R/AMYR) dual agonists, and triple agonists achieve weight loss beyond traditional single agents through synergistic regulation of appetite, energy metabolism, and lipolysis. In multi-drug combination therapy, free combinations offer flexibility, while fixed-dose combinations improve convenience and adherence. These strategies improve weight loss and metabolic outcomes, including hepatic fat and cardiometabolic parameters. In terms of safety, gastrointestinal events are the most common. However, as the number of targets increases and doses escalate, potential risks such as increased heart rate and hypoglycemia warrant attention, with particular consideration for thyroid and muscle safety during long-term use. Future research should focus on optimizing personalized treatment strategies, conducting head-to-head comparisons of agents with different mechanisms, developing oral formulations, and exploring long-term maintenance regimens to advance comprehensive obesity management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityGlucagon-Like Peptide 1HumansAnimalsDrug Therapy, CombinationGlucagon-Like Peptide-1 ReceptorReceptors, Gastrointestinal Hormone

Stichwörter der Autor:innen

Combination therapyGLP-1 receptor agonistsMulti-target agonistsObesityWeight loss

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorReceptors, Gastrointestinal Hormone

Autor:innen und Institutionen

  • Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai University…
  • Institute of Interdisciplinary Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; State Key Laboratory of Discovery and Utilization of Functional Components in Traditiona…

Förderung

  • National Natural Science Foundation of China
  • Shanghai University of Traditional Chinese Medicine
  • National Administration of Traditional Chinese Medicine
  • Shanghai Pudong New Area Health Commission
  • Shanghai Lingjun Program

Zitieren

APA

Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026). GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108331

Vancouver

Wang X, Lin R, Sun Q, Xin X, Feng Q. GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108331

BibTeX
@article{Wang2026,
  author = {Wang, Xinyao and Lin, Rutao and Sun, Qinmei and Xin, Xin and Feng, Qin},
  title = {GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies},
  journal = {Pharmacological Research},
  year = {2026},
  doi = {10.1016/j.phrs.2026.108331}
}
Kostenlos starten →